Product Development Report (PDR) MCQs With Answer

Product Development Report (PDR) MCQs With Answer

This blog delivers a focused set of multiple-choice questions designed to deepen M.Pharm students’ understanding of the Product Development Report (PDR). The PDR is a comprehensive document that captures formulation rationale, development experiments, manufacturing scale-up, analytical methods, stability data, regulatory considerations and quality risk assessments. These MCQs probe core concepts such as PDR structure, critical sections, regulatory expectations, comparability, validation and technology transfer. Each question aims to build practical knowledge for writing, reviewing or using PDRs during development and submission activities. Use these targeted items to assess readiness for academic exams, project work and industry roles in documentation and regulatory writing.

Q1. What is the primary purpose of a Product Development Report (PDR)?

• To provide marketing strategies for product launch
• To document the scientific basis and development history of a drug product
• To replace the clinical study reports in regulatory submissions
• To list distribution channels and pricing

Correct Answer: To document the scientific basis and development history of a drug product

Q2. Which section of a PDR typically summarizes formulation selection, development studies and rationale for excipient choices?

• Manufacturing batch record
• Analytical validation section
• Formulation development and rationale section
• Marketing and commercial strategy section

Correct Answer: Formulation development and rationale section

Q3. Which element is essential in the PDR’s analytical methods section?

• Detailed social media plan for method promotion
• Full chromatographic conditions, validation parameters and method suitability data
• Only the list of instruments used without parameters
• Forecasted cost per analysis

Correct Answer: Full chromatographic conditions, validation parameters and method suitability data

Q4. When preparing a PDR for regulatory communication, which stability-related content is most critical?

• Only accelerated stability data with no protocol description
• Storage conditions recommended by marketing team
• Stability study protocols, full data (accelerated and long-term), and trending analysis
• Photographs of samples stored in office conditions

Correct Answer: Stability study protocols, full data (accelerated and long-term), and trending analysis

Q5. How does a Product Development Report differ from a regulatory dossier?

• PDR is purely promotional while dossier is technical
• PDR documents internal development history and rationale; a dossier is a regulatory submission package containing finalized data and modules
• They are the same document with different names
• PDR is only for clinical data while dossier is only for manufacturing

Correct Answer: PDR documents internal development history and rationale; a dossier is a regulatory submission package containing finalized data and modules

Q6. At what stage of product lifecycle is the PDR typically prepared?

• Only after product marketing begins
• During formulation development and scale-up, and updated until final transfer to commercial manufacture
• Only during post-marketing surveillance
• After patent expiry

Correct Answer: During formulation development and scale-up, and updated until final transfer to commercial manufacture

Q7. Which of the following best describes the ideal authorship and review responsibility for a PDR?

• Authored solely by the marketing department
• Authored by cross-functional team members (R&D, analytical, QA, manufacturing) with QA/Regulatory review
• Prepared exclusively by external consultants with no internal review
• Written by summer interns without expert oversight

Correct Answer: Authored by cross-functional team members (R&D, analytical, QA, manufacturing) with QA/Regulatory review

Q8. What is the role of risk assessment (e.g., FMEA) within a PDR?

• To replace stability studies entirely
• To identify, prioritize and propose controls for potential development and manufacturing risks
• To provide marketing risk analysis for sales forecasts
• To list cosmetic risks associated with packaging aesthetics

Correct Answer: To identify, prioritize and propose controls for potential development and manufacturing risks

Q9. Which information is necessary in the manufacturing and scale-up section of a PDR?

• Only the theoretical yield without process parameters
• Process flow diagrams, critical process parameters, scale-up data and in-process controls
• Exclusive focus on final tablet weight
• Commercial sales projections

Correct Answer: Process flow diagrams, critical process parameters, scale-up data and in-process controls

Q10. Which statement about product specifications in the PDR is correct?

• Specifications should be vague to allow flexibility
• Specifications should define acceptance criteria for drug substance and drug product including critical attributes and test methods
• Specifications are optional until regulatory submission
• Specifications only include visual appearance

Correct Answer: Specifications should define acceptance criteria for drug substance and drug product including critical attributes and test methods

Q11. What content relating to analytical method validation should be included in a PDR?

• Only the method name without validation data
• Validation protocol, results for accuracy, precision, specificity, linearity, LOD/LOQ and robustness
• Only a reference to a pharmacopeia without in-house data
• Marketing claims about method superiority

Correct Answer: Validation protocol, results for accuracy, precision, specificity, linearity, LOD/LOQ and robustness

Q12. How should changes made during development (e.g., supplier change) be handled in the PDR?

• Changes need not be documented if product passes final test
• Documented with rationale, risk assessment, comparability data and impact on specifications or stability
• Reported only to procurement
• Only verbally communicated during meetings

Correct Answer: Documented with rationale, risk assessment, comparability data and impact on specifications or stability

Q13. Which of the following best describes comparability data in a PDR?

• Non-critical cosmetic comparisons between batches
• Analytical and performance data demonstrating equivalence after changes to materials, process or site
• Only dissolution profiles without impurity data
• Marketing comparisons with competitor products

Correct Answer: Analytical and performance data demonstrating equivalence after changes to materials, process or site

Q14. What is expected in the PDR regarding pilot and scale-up batches?

• Only the name of the pilot plant is required
• Detailed batch records, yields, in-process results, deviations and lessons learned
• Only small-scale lab notebook entries
• Only final commercial batch data

Correct Answer: Detailed batch records, yields, in-process results, deviations and lessons learned

Q15. Which validation activities should be summarized in the PDR?

• Analytical, process, cleaning and computer system validations with acceptance criteria and outcomes
• Only cleaning validation for non-contact areas
• Validation plans without results
• Only vendor validation certificates without in-house data

Correct Answer: Analytical, process, cleaning and computer system validations with acceptance criteria and outcomes

Q16. Which stability-indicating characteristics should be justified and presented in a PDR?

• Only color change observations
• Selection of stability-indicating assays, degradation profiles, specification limits and packaging impact
• Only photostability results with no assay data
• Only long-term data without accelerated or intermediate studies

Correct Answer: Selection of stability-indicating assays, degradation profiles, specification limits and packaging impact

Q17. Why is packaging selection and evaluation an important PDR section?

• Packaging only affects aesthetics and is not important
• Packaging protects product integrity, affects stability and user safety; testing and rationale must be presented
• To ensure lowest cost regardless of compatibility
• Because it determines the marketing color scheme

Correct Answer: Packaging protects product integrity, affects stability and user safety; testing and rationale must be presented

Q18. What labeling and patient information considerations are included in a PDR?

• Complete label text, dosing instructions, storage conditions, warnings and justification for content
• Only the company logo
• Pricing and discount codes
• Social media hashtags

Correct Answer: Complete label text, dosing instructions, storage conditions, warnings and justification for content

Q19. How does the PDR facilitate technology transfer to manufacturing?

• By providing only marketing materials
• By transferring process knowledge: critical quality attributes, CPPs, batch records, scale-up data and contingency measures
• By sending a one-page summary without technical detail
• By outsourcing all responsibility to the receiving site

Correct Answer: By transferring process knowledge: critical quality attributes, CPPs, batch records, scale-up data and contingency measures

Q20. Which statement correctly describes intellectual property and confidentiality handling in a PDR?

• PDRs should be publicly posted without redaction
• PDRs often contain proprietary data and should be controlled, access-limited and redacted appropriately before external sharing
• PDRs do not contain any confidential information
• PDRs only require oral confidentiality agreements

Correct Answer: PDRs often contain proprietary data and should be controlled, access-limited and redacted appropriately before external sharing

Download